TERN · Terns Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | $0 | $0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $77.89M | $70.11M | $63.50M | $39.62M | $28.03M |
| SG&A | $32.23M | $31.76M | $39.06M | $22.41M | $9.00M |
| Total Operating Expenses | $110.12M | $101.87M | $102.56M | $62.03M | $37.02M |
| D&A | $90.0K | $319.0K | $292.0K | $484.0K | $394.0K |
| Operating Income | ($110.12M) | ($101.87M) | ($102.56M) | ($62.03M) | ($37.02M) |
| Interest Expense | - | - | - | - | - |
| Income Tax | $581.0K | $260.0K | $239.0K | $358.0K | $813.0K |
| Net Income | ($96.21M) | ($88.85M) | ($90.21M) | ($60.34M) | ($40.05M) |
| EPS - Basic | ($1.03) | ($1.12) | ($1.27) | ($1.67) | - |
| EPS - Diluted | ($1.03) | ($1.12) | ($1.27) | ($1.67) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $524.75M | $161.44M | $79.93M | $143.24M | $47.70M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $1.72M | $2.15M | $2.52M | $1.65M | $2.13M |
| Current Assets | $1.02B | $362.11M | $267.43M | $285.19M | $166.93M |
| Total Assets | $1.03B | $363.93M | $268.52M | $287.03M | $168.07M |
| Current Liabilities | $16.41M | $15.65M | $11.94M | $8.47M | $6.82M |
| Long-term Debt | - | - | $0 | $544.0K | - |
| Total Liabilities | $18.55M | $18.06M | $13.15M | $10.08M | $7.77M |
| Stockholders' Equity | $1.01B | $345.87M | $255.37M | $276.94M | $160.30M |
| Retained Earnings | ($517.69M) | ($421.48M) | ($332.63M) | ($242.42M) | ($182.07M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($82.18M) | ($70.02M) | ($67.39M) | ($49.11M) | ($29.81M) |
| Investing Cash Flow | ($298.04M) | ($12.41M) | ($37.99M) | ($22.27M) | $6.69M |
| Financing Cash Flow | $743.51M | $164.00M | $41.95M | $167.09M | $85.52M |
| CapEx | $0 | $42.0K | $52.0K | $275.0K | $584.0K |
| Free Cash Flow | ($82.18M) | ($70.06M) | ($67.44M) | ($49.38M) | ($30.39M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | 0.85 | 0.79 | 0.75 | 0.82 | 0.76 |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -9.4% | -24.4% | -33.6% | -21.0% | -23.8% |
| Return on equity | -9.6% | -25.7% | -35.3% | -21.8% | -25.0% |
| Return on invested capital | - | - | -31.7% | -17.7% | - |
| Liquidity | |||||
| Current ratio | 62.41 | 23.14 | 22.39 | 33.68 | 24.48 |
| Quick ratio | 62.41 | 23.14 | 22.39 | 33.68 | 24.48 |
| Cash ratio | 31.98 | 10.32 | 6.69 | 16.91 | 6.99 |
| Leverage | |||||
| Debt / Equity | - | - | 0.00 | 0.00 | - |
| Debt / Assets | - | - | 0.00 | 0.00 | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | 1.02 | 1.05 | 1.05 | 1.04 | 1.05 |
| Liabilities / Assets | 0.02 | 0.05 | 0.05 | 0.04 | 0.05 |
| Efficiency | |||||
| Asset turnover | - | - | - | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 3.7x | 1.3x | 1.8x | 0.8x | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | -8.1% | 0.7% | -65.3% | -67.5% | - |
| Net income growth (YoY) | -8.3% | 1.5% | -49.5% | -50.7% | - |
| EPS growth (YoY) | 8.0% | 11.8% | 24.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -17.3% | -3.9% | -36.6% | -62.5% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 191.0% | 35.4% | -7.8% | 72.8% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Terns Pharmaceuticals against the 5 most active filers in the same SIC group.